Lates News

According to AI Express of Every Economy, Dongxing Securities released a research report on August 25th recommending a buy rating for Shenzhen Hepalink Pharmaceutical Co., Ltd (600201.SH). The main reasons for the rating include: 1) intense industry competition, with the company prioritizing quantity over price; 2) focusing on research and development innovation, resulting in multiple breakthroughs in new products. (Daily Economic News)